Study guide
7.1 Chronic GVHD: Three-Phase Immunobiology & NIH Classification
Transplantation and Cellular Therapy Certified Nurse TCTCN
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 The TCTCN Credential: Rename, Scope & Official Test Blueprint 1.2 TCTCN Eligibility, Test-Day Logistics, Scoring & Renewal 1.3 Building the Study Plan & Clinical Prioritization Framework 1.4 Clinical Triage Rehearsal & Exam-Day Question Strategy
2 Chapter 2: Foundations of Transplantation & Cellular Biology
2.1 Hematopoietic Lineage, the MHC & HLA Class I vs Class II Biology 2.2 HLA Typing Resolution, Donor Matching, DSA & ABO Compatibility 2.3 Disease Indications & the Cellular Therapy Modality Map 2.4 Pre-Transplant Risk Stratification & Organ Suitability Assessment 2.5 Stem Cell & Cellular Product Sources: Donor Selection Hierarchy 2.6 Conditioning Regimens & Lymphodepletion Principles 2.7 Recipient and Caregiver Education Across the Continuum
3 Chapter 3: Product Collection, Processing & Infusion Procedures
3.1 Stem Cell Mobilization: Niche Biology, Agents & CD34+ Collection Targets 3.2 Apheresis Nursing Care: Vascular Access, Citrate Toxicity & Donor Safety 3.3 Graft Engineering, ABO-Directed Processing & Cryopreservation Science 3.4 DMSO Toxicity, Premedication & Time-Critical Thawed Product Administration 3.5 Pre-Administration Verification, Equipment & CAR T Infusion Readiness 3.6 Infusion Monitoring & Acute Reaction Differential Management 3.7 Engraftment Definitions, Kinetics & Factors Impairing Recovery 3.8 Graft Failure Classification & Donor Chimerism Tracking
4 Chapter 4: Acute Post-HSCT Complications & Graft-versus-Host Disease
4.1 Acute GVHD: Billingham's Postulates, Classification & the Ferrara 3-Phase Model 4.2 Acute GVHD Organ Manifestations, Histopathology & MAGIC Staging 4.3 MAGIC Overall Grading & Acute GVHD Plasma Biomarkers 4.4 Acute GVHD Prophylaxis, First-Line Steroids & Steroid-Refractory Therapy 4.5 SOS/VOD: Microvascular Pathophysiology & Risk Stratification 4.6 SOS/VOD Diagnostic Criteria, Surveillance & Defibrotide Therapy 4.7 TA-TMA: Complement Pathophysiology, Harmonized Criteria & Differential 4.8 TA-TMA Management, Complement-Directed Therapy & Other Endothelial Syndromes
5 Chapter 5: Post-Transplant Infections & Supportive Care
5.1 Neutropenic Fever, Pre-Engraftment Phase & Empiric Antimicrobial Therapy 5.2 CMV: Risk Stratification, Letermovir Prophylaxis & DNAemia Treatment 5.3 EBV/PTLD, HHV-6 Encephalitis, BK Cystitis, Adenovirus, HSV & VZV 5.4 Invasive Fungal Infections (Aspergillus, Candida, Mucor) & PJP Prophylaxis 5.5 Supportive Care in Aplasia: Transfusion Guidelines, Oral Mucositis & Nutrition
6 Chapter 6: Post-Cellular Therapy Management, CRS & ICANS
6.1 CAR Structural Architecture, Generations & Costimulatory Domain Biology 6.2 The Vein-to-Vein Lifecycle, In Vivo Kinetics & On-Target B-Cell Aplasia 6.3 CRS Pathophysiology, Clinical Kinetics & Inflammatory Biomarkers 6.4 ASTCT CRS Grading, Tocilizumab & Escalation Management 6.5 ICANS: Assessment, ICE Scoring & Clinical Management 6.6 Delayed Cellular Toxicities: Prolonged Cytopenias, B-Cell Aplasia & IEC-HS 6.7 Symptom Management and Functional Recovery After Cellular Therapy
7 Chapter 7: Chronic GVHD & Long-Term Survivorship
7.1 Chronic GVHD: Three-Phase Immunobiology & NIH Classification 7.2 Chronic GVHD Diagnostic Manifestations, BOS & NIH Global Severity Scoring 7.3 Chronic GVHD: Systemic, Steroid-Sparing & Multidisciplinary Therapy 7.4 Late Effects: Endocrine, Cardiovascular, Bone Health & Secondary Malignancies 7.5 Immune Reconstitution & the Inactivated Re-Vaccination Schedule 7.6 Live Vaccines, Household Contact Precautions & Survivorship Care Plans 7.7 Post-HSCT Relapse: Surveillance, Immunologic Manipulation & Treatment
8 Chapter 8: Quality of Life, Ethics & Professional Practice Standards
8.1 Psychosocial Trajectories, Distress Screening & Delirium Assessment 8.2 Caregiver Planning, Financial & Cultural Navigation, and Sexual Health 8.3 Palliative Care Integration, Advance Directives & Ethical Considerations 8.4 FACT-JACIE Quality Standards, CIBMTR / NMDP Reporting & Compliance 8.5 Evidence-Based Practice, Discharge Education & Quality Improvement
7.1 Chronic GVHD: Three-Phase Immunobiology & NIH Classification
Key Takeaways Explain This Topic AI
Chronic GVHD is defined by clinical morphology and organ findings, not a day +100 cutoff; acute-type features after day 100 remain late acute GVHD, while overlap includes both acute and chronic features.
Phase 2 of chronic GVHD biology centers on thymic injury: destruction of medullary thymic epithelial cells impairs AIRE expression and central negative selection, letting autoreactive and alloreactive donor T-cell clones escape into the periphery.
Regulatory T-cell depletion and excess B-cell activating factor (BAFF) relative to naive B cells drive autoantibody production against targets including PDGFR-alpha, nuclear antigens, and H-Y minor histocompatibility antigens.
Phase 3 fibrosis is driven by TGF-beta and PDGF signaling through ROCK2 and SMAD2/3, which transdifferentiate fibroblasts into alpha-SMA-expressing myofibroblasts that deposit types I and III collagen - explaining cutaneous sclerosis, fascial tightening, and bronchiolar obliteration.
This loss-of-tolerance and fibrotic biology, rather than the predominantly cytotoxic alloreactivity of acute GVHD, is what makes chronic GVHD resemble an autoimmune syndrome.
Last updated: September 2026
Chronic GVHD: NIH Consensus Diagnostic Criteria & Clinical Manifestations
Quick Clinical Summary: Chronic Graft-versus-Host Disease (cGVHD) is the leading cause of late non-relapse morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT), affecting 30% to 70% of long-term survivors. Driven by thymic epithelial injury, loss of central and peripheral immune tolerance, auto- and alloreactive T- and B-cell activation, and progressive TGF-beta/PDGF-mediated fibrogenesis, cGVHD mimics systemic autoimmune disorders such as scleroderma, Sjogren's syndrome, and lichen planus. The National Institutes of Health (NIH) Consensus Criteria have eliminated the historical "Day +100" time threshold, establishing rigorous clinical definitions for Classic Chronic GVHD and Overlap Syndrome based on diagnostic and distinctive organ features across eight major organ systems.
1. Immunological Pathophysiology: The Three-Phase Model
Unlike acute GVHD, which is primarily an acute cytolytic storm driven by donor mature T-cell alloreactivity against host histocompatibility antigens, chronic GVHD develops as a complex, multistage autoimmune and fibrotic disorder. The contemporary paradigm organizes cGVHD pathogenesis into three interconnected phases: THREE-PHASE PATHOPHYSIOLOGY OF cGVHD
- [ Phase 1: Early Inflammation & Tissue Injury ]
- * Conditioning (Chemo / TBI) + PAMPs / DAMPs + Acute GVHD residual inflammation
- * Macrophage / DC activation -> Secretion of IL-1, TNF-alpha, IL-6, IFN-gamma
- |
- v
- [ Phase 2: Chronic Inflammation, Thymic Injury & Loss of Immune Tolerance ]
- * Medullary Thymic Epithelial Cell (mTEC) injury -> Loss of AIRE expression
- * Impaired central negative selection -> Escape of autoreactive CD4+ & CD8+ T cells
- * Deficiency of FoxP3+ Regulatory T cells (Tregs) -> Loss of peripheral tolerance
- * Aberrant B-cell activation -> Elevated BAFF levels + Anti-PDGF receptor autoantibodies
- * Germinal center Tfh & Th17 polarization -> Sustained pro-inflammatory signaling
- |
- v
- [ Phase 3: Tissue Repair, Fibroblast Activation & Fibrosis ]
- * Macrophages & Alloreactive T cells release TGF-beta & PDGF-alpha
- * Activation of Rho-associated coiled-coil kinase 2 (ROCK2) signaling
- * Transdifferentiation of resting fibroblasts into alpha-SMA+ contractile myofibroblasts
- * Excessive extracellular matrix & collagen deposition -> Sclerosis, BOS, joint contractures
- Phase 1: Early Inflammation and Endothelial/Epithelial Injury
Triggers: High-dose myeloablative conditioning chemotherapy, total body irradiation (TBI), pre-existing acute GVHD damage, and translocation of pathogen-associated molecular patterns (PAMPs, e.g., LPS) and damage-associated molecular patterns (DAMPs, e.g., uric acid, HMGB1).
Innate Activation: Recipient antigen-presenting cells (APCs) and donor-derived dendritic cells become hyperactivated, secreting inflammatory cytokines (TNF-alpha, IL-1, IL-6, IFN-gamma) and chemoattractants that recruit donor immune effectors into host target tissues (skin, liver, mucosal surfaces, lungs).
Phase 2: Thymic Damage, Immune Dysregulation & Loss of Tolerance
Thymic Microenvironment Disruption: Conditioning and alloreactive donor T cells destroy medullary thymic epithelial cells (mTECs) and cortical epithelial niches. This impairs autoimmune regulator ( AIRE ) expression and disrupts central negative selection, permitting newly developing autoreactive and alloreactive donor T-cell clones to escape into the periphery.
Regulatory T-Cell (Treg) Exhaustion: Peripheral CD4+CD25+FoxP3+ regulatory T cells undergo marked quantitative and qualitative depletion, failing to suppress autoreactive effector clones.
B-Cell Dysregulation & Autoantibody Production: Excessive levels of B-cell activating factor ( BAFF ) relative to naive B-cell counts promote survival and hyperactivation of autoreactive B cells. Activated B cells act as potent APCs and secrete pathogenic autoantibodies directed against platelet-derived growth factor receptors ( anti-PDGFR-alpha ), nuclear antigens (ANA), and minor histocompatibility antigens (H-Y), driving sustained tissue signaling.
Th17 and T Follicular Helper (Tfh) Shift: Disrupted immune balance promotes IL-17- and IL-21-secreting T-cell subsets, facilitating germinal center B-cell expansion and macrophage recruitment.
Phase 3: Tissue Repair, Fibroblast Activation & End-Stage Sclerosis
Macrophage & Fibroblast Crosstalk: Infiltration of profibrotic M2 macrophages and alloreactive T cells leads to high local concentrations of Transforming Growth Factor-beta ( TGF-beta ) and Platelet-Derived Growth Factor ( PDGF ).
Myofibroblast Differentiation: Engagement of TGF-beta receptors and PDGF receptors stimulates intracellular ROCK2 (Rho-associated coiled-coil kinase 2) and SMAD2/3 signaling cascades. Resting tissue fibroblasts transdifferentiate into alpha-smooth muscle actin (alpha-SMA)-expressing myofibroblasts .
Extracellular Matrix Deposition: Myofibroblasts constitutively produce excessive types I and III collagen, fibronectin, and proteoglycans, obliterating normal tissue architecture. Microvascular rarefaction, deep fascial tightening, cutaneous sclerosis, and luminal obliteration in terminal bronchioles (BOS) result.
2. NIH Consensus Classification & Timing Definitions
Historically, GVHD occurring before Day +100 was termed "acute," and GVHD after Day +100 was termed "chronic." The NIH Consensus Conferences officially retired this arbitrary time-based threshold, replacing it with a clinicopathologic framework based strictly on clinical presentation and morphology.
Category Time of Onset Acute GVHD Features Chronic GVHD Features Pathologic & Clinical Context
Classic Acute GVHD Typically <= 100 days post-HCT (or post-DLI) Present (erythematous maculopapular rash, secretory diarrhea, cholestatic jaundice) Absent Classic cytolytic target organ involvement.
Late-Onset Acute GVHD >100 days post-HCT Present (pure acute features: erythema, nausea/vomiting, large-volume diarrhea, hyperbilirubinemia) Absent Often precipitated by early immunosuppression taper or donor lymphocyte infusion (DLI).
Classic Chronic GVHD Variable (typically >100 days, but can occur earlier) Absent Present (at least one diagnostic chronic feature OR distinctive feature + confirmation) Sclerotic skin, oral lichenoid changes, BOS, keratoconjunctivitis sicca, fascial thickening.
Overlap syndrome Variable (any time post-HCT) Present Present Contains both acute- and chronic-GVHD features; prognosis and treatment depend on involved organs, activity, severity, infection and response rather than the label alone.
NIH diagnostic rule: After excluding alternative causes, chronic GVHD requires at least one diagnostic manifestation, or one distinctive manifestation supported by pertinent biopsy, laboratory/radiologic testing, specialist assessment, or chronic-GVHD evidence in another organ. “Diagnostic” is the consensus term; not every such finding is pathognomonic.